
FDA will hold a symposium discussing the identification of concepts and terminology for multi-component biomarkers from March 23–24, 2022.
FDA will hold a symposium discussing the identification of concepts and terminology for multi-component biomarkers from March 23–24, 2022.
FDA has granted Eli Lilly and Company’s bebtelovimab, a monoclonal antibody designed for treatment of COVID-19, an Emergency Use Authorization (EUA).
The agency recommended 53 new active substances in 2021, up 35% from 2020.
The agency’s safety committee is assessing reported cases of period irregularities associated with Comirnaty and Spikevax mRNA vaccines.
Guidance published during the pandemic has been updated to include content requirements for summary safety reports.
Novavax’s COVID-19 vaccine has received conditional marketing authorization from MHRA and provisional approval from Medsafe.
EMA has started its evaluation of an application for the use of a booster dose of Comirnaty in adolescents aged 12–15 years.
EMA has started the establishment of its Data Analysis and Real World Interrogation Network (DARWIN EU) Coordination Centre.
FDA has approved sutimlimab-jome as a treatment for hemolysis in individuals with CAD.
Sartorius Stedim Biotech has completed the acquisition of the chromatography equipment division of Novasep.
The European Patent Office has granted another patent to Salipro Biotech, covering the composition-of-matter, methods, and uses of the company’s novel antigen technology.
CGT Catapult has partnered with MICA Biosystems to advance MICA’s regenerative medicine technology to the UK’s MHRA.
With new COVID-19 infections declining, the agency is resuming domestic inspections of drug manufacturing facilities.
The agency approved Roche’s Vabysmo to treat neovascular or “wet” age-related macular degeneration and diabetic macular edema.
A range of political issues have impacted FDA initiatives vital to the agency’s effectiveness and stature, both at home and on the important global stage.
Janssen has submitted a MAA to the EMA for teclistamab as a treatment of relapsed or refractory multiple myeloma (RRMM).
The draft PREVENT Pandemic Act aims to secure supply chains, expand health data collection, and support access to vital medical products
BIA and Clarivate have released new data that show there was a jump of 60% in investments into biotech and life sciences companies in the UK during 2021.
Delays in sponsors providing postapproval evidence of effectiveness for therapies benefitting from streamlined FDA regulatory pathways are generating pressure for further review and reform of the agency’s accelerated approval process.
A report by international regulators reviews the effectiveness of current COVID-19 vaccines against the omicron variant.
The company is voluntarily recalling one batch of Semglee prefilled pens because of a potential missing label.
The agency discusses its response to COVID-19 and other milestones in its year-end review.
The agency’s COVID-19 task force says latest data shows use of COVID-19 mRNA vaccines during pregnancy is safe.
The UK’s National Institute of Health and Care Excellence has recommended the use of Janssen’s Darzalex (daratumumab) in combination with Velcade (bortezomib), thalidomide and dexamethasone (DVTd) to treat adults with multiple myeloma.
The Centers for Medicare and Medicaid Services took action to limit prescribing and use of Biogen’s new and controversial Alzheimer’s treatment Aduhelm (aducanumab).
FDA amended it’s Emergency Use Authorization to shorten Moderna’s vaccine booster dose interval from six to five months.
FDA maintained a steady pace in 2021 in approving important new therapies for market, including new vaccines and treatments for COVID-19.
The agency is expanding the use of a single booster of the Pfizer-BioNTech vaccine to children ages 12–15 and is shortening the time between primary vaccination and booster to at least five months.
FDA authorized emergency use of Pfizer’s oral antiviral drug to make the drug available as quickly as possible.
The agency recommended granting conditional marketing authorization for use of Nuvaxovid in people 18 years of age and older.